Intra-Cellular (ITCI) | Financial Analysis & Statements
Intra-Cellular Therapies Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2024Income Metrics
Revenue
199.2M
Gross Profit
178.8M
89.76%
Operating Income
-29.2M
-14.66%
Net Income
-16.9M
-8.48%
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
218.5M
Shareholders Equity
1.1B
Debt to Equity
0.19
Cash Flow Metrics
Operating Cash Flow
-16.9M
Free Cash Flow
-12.7M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2024
Annual Income Flow
2024
Intra-Cellular Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 680.5M | 462.2M | 249.1M | 81.7M | 22.5M |
| Cost of Goods Sold | 57.0M | 33.7M | 20.4M | 8.0M | 1.9M |
| Gross Profit | 623.5M | 428.4M | 228.7M | 73.7M | 20.6M |
| Gross Margin % | 91.6% | 92.7% | 91.8% | 90.2% | 91.6% |
| Operating Expenses | |||||
| Research & Development | 236.1M | 180.1M | 134.7M | 88.8M | 65.8M |
| Selling, General & Administrative | 504.5M | 409.9M | 358.8M | 272.6M | 186.4M |
| Other Operating Expenses | -351.0K | -2.2M | -1.2M | -2.1M | -282.0K |
| Total Operating Expenses | 740.3M | 587.8M | 492.3M | 359.4M | 251.9M |
| Operating Income | -116.7M | -159.4M | -263.6M | -285.7M | -231.2M |
| Operating Margin % | -17.2% | -34.5% | -105.8% | -349.6% | -1,026.3% |
| Non-Operating Items | |||||
| Interest Income | 42.5M | 20.3M | 7.4M | 1.6M | 4.2M |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -74.2M | -139.0M | -256.2M | -284.1M | -227.0M |
| Income Tax | 473.0K | 636.0K | 6.0K | 6.0K | 14.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -74.7M | -139.7M | -256.3M | -284.1M | -227.0M |
| Net Margin % | -11.0% | -30.2% | -102.9% | -347.7% | -1,007.5% |
| Key Metrics | |||||
| EBITDA | -116.2M | -158.9M | -263.0M | -285.2M | -230.7M |
| EPS (Basic) | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 |
| EPS (Diluted) | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 |
| Basic Shares Outstanding | 103131017 | 95881729 | 94046670 | 81253394 | 70364800 |
| Diluted Shares Outstanding | 103131017 | 95881729 | 94046670 | 81253394 | 70364800 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Intra-Cellular Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 306.9M | 147.8M | 148.6M | 92.4M | 60.0M |
| Short-term Investments | 694.1M | 350.2M | 443.3M | 320.0M | 597.4M |
| Accounts Receivable | 166.5M | 114.0M | 75.2M | 20.2M | 10.8M |
| Inventory | 26.3M | 11.6M | 23.9M | 7.9M | 7.1M |
| Other Current Assets | 111.8M | 42.4M | 45.2M | 25.4M | 14.2M |
| Total Current Assets | 1.3B | 667.8M | 738.0M | 467.3M | 690.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 14.9M | 14.6M | 16.7M | 25.1M | 28.5M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 44.7M | 45.9M | 86.0K | 86.0K | 86.1K |
| Total Non-Current Assets | 59.5M | 60.5M | 16.8M | 22.6M | 26.4M |
| Total Assets | 1.4B | 728.3M | 754.8M | 489.9M | 717.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 26.1M | 11.5M | 10.4M | 8.7M | 5.5M |
| Short-term Debt | 4.2M | 3.6M | 4.6M | 6.7M | 5.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 205.7M | 123.5M | 83.2M | 53.4M | 36.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 12.7M | 13.3M | 15.5M | 18.7M | 23.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 12.7M | 13.3M | 15.5M | 18.7M | 23.6M |
| Total Liabilities | 218.5M | 136.9M | 98.7M | 72.0M | 60.5M |
| Equity | |||||
| Common Stock | 11.0K | 10.0K | 9.0K | 8.0K | 8.0K |
| Retained Earnings | -1.7B | -1.6B | -1.5B | -1.2B | -937.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.1B | 591.4M | 656.1M | 417.9M | 656.9M |
| Key Metrics | |||||
| Total Debt | 17.0M | 16.9M | 20.0M | 25.4M | 29.1M |
| Working Capital | 1.1B | 544.3M | 654.7M | 413.9M | 654.1M |
Balance Sheet Composition
Intra-Cellular Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -74.7M | -139.7M | -256.3M | -284.1M | -227.0M |
| Depreciation & Amortization | 508.0K | 528.0K | 656.0K | 533.0K | 528.0K |
| Stock-Based Compensation | 64.0M | 52.8M | 43.0M | 34.3M | 24.1M |
| Working Capital Changes | -53.2M | -65.3M | -68.7M | -7.3M | -19.6M |
| Operating Cash Flow | -63.3M | -151.5M | -281.2M | -256.4M | -221.7M |
| Investing Activities | |||||
| Capital Expenditures | -322.0K | -269.0K | -778.0K | -325.0K | -267.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -739.7M | -415.3M | -759.2M | -224.6M | -755.6M |
| Investment Sales | 404.9M | 521.1M | 631.6M | 505.2M | 275.6M |
| Investing Cash Flow | -335.2M | 105.5M | -128.4M | 280.3M | -480.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 543.1M | 0 | 433.7M | 0 | 652.7M |
| Free Cash Flow | -73.5M | -124.5M | -271.0M | -259.9M | -230.3M |
| Net Change in Cash | 144.7M | -46.0M | 24.1M | 24.0M | -49.3M |
Cash Flow Trend
Intra-Cellular Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-183.15
Forward P/E
507.19
Price to Book
12.20
Price to Sales
20.63
PEG Ratio
507.19
Profitability Ratios
Profit Margin
-10.97%
Operating Margin
-14.66%
Return on Equity
-8.58%
Return on Assets
-6.96%
Financial Health
Current Ratio
6.36
Debt to Equity
1.48
Beta
0.46
Per Share Data
EPS (TTM)
$-0.73
Book Value per Share
$10.81
Revenue per Share
$6.60
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ITCI | 14.0B | -183.15 | 12.20 | -8.58% | -10.97% | 1.48 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| United Therapeutics | 25.1B | 20.60 | 3.53 | 19.72% | 41.94% | 0.53 |
| Neurocrine | 13.1B | 27.88 | 4.01 | 16.38% | 16.73% | 14.49 |
| Viatris | 17.0B | 235.80 | 1.15 | -21.08% | -24.58% | 99.91 |
Financial data is updated regularly. All figures are in the company's reporting currency.
